213 related articles for article (PubMed ID: 29360538)
21. G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation.
Akiyama T; Sugiyama K; Shimizu M; Tamaoki T; Akinaga S
Jpn J Cancer Res; 1999 Dec; 90(12):1364-72. PubMed ID: 10665655
[TBL] [Abstract][Full Text] [Related]
22. Cell cycle-related kinase in carcinogenesis.
Tian Y; Wan H; Tan G
Oncol Lett; 2012 Oct; 4(4):601-606. PubMed ID: 23205069
[TBL] [Abstract][Full Text] [Related]
23. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
24. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.
Gomatou G; Trontzas I; Ioannou S; Drizou M; Syrigos N; Kotteas E
Mol Biol Rep; 2021 Jan; 48(1):915-925. PubMed ID: 33409716
[TBL] [Abstract][Full Text] [Related]
26. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
27. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
28. BROMI/TBC1D32 together with CCRK/CDK20 and FAM149B1/JBTS36 contributes to intraflagellar transport turnaround involving ICK/CILK1.
Satoda Y; Noguchi T; Fujii T; Taniguchi A; Katoh Y; Nakayama K
Mol Biol Cell; 2022 Aug; 33(9):ar79. PubMed ID: 35609210
[TBL] [Abstract][Full Text] [Related]
29. Cell cycle-related kinase is a crucial regulator for ciliogenesis and Hedgehog signaling in embryonic mouse lung development.
Lee H; Ko HW
BMB Rep; 2020 Jul; 53(7):367-372. PubMed ID: 32317081
[TBL] [Abstract][Full Text] [Related]
30. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
31. TGF-β/activin signaling promotes CDK7 inhibitor resistance in triple-negative breast cancer cells through upregulation of multidrug transporters.
Webb BM; Bryson BL; Williams-Medina E; Bobbitt JR; Seachrist DD; Anstine LJ; Keri RA
J Biol Chem; 2021 Oct; 297(4):101162. PubMed ID: 34481843
[TBL] [Abstract][Full Text] [Related]
32. Signal transducer and activator of transcription 3 cooperates with androgen receptor/cell cycle-related kinase signalling pathway in the progression of hepatitis B virus infection and gender differences.
Xu Y; Qi W; Wang X; Zhang Y; Han L; Shi J; Wang G; Liu J; Duan H; Cong X; Zhao P; Zhou C; Wang J
J Viral Hepat; 2022 Jul; 29(7):569-578. PubMed ID: 35567395
[TBL] [Abstract][Full Text] [Related]
33. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
34. Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation.
Baldassarre G; Barone MV; Belletti B; Sandomenico C; Bruni P; Spiezia S; Boccia A; Vento MT; Romano A; Pepe S; Fusco A; Viglietto G
Oncogene; 1999 Nov; 18(46):6241-51. PubMed ID: 10597222
[TBL] [Abstract][Full Text] [Related]
35. P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
Grimison B; Langan TA; Sclafani RA
Cell Growth Differ; 2000 Oct; 11(10):507-15. PubMed ID: 11063124
[TBL] [Abstract][Full Text] [Related]
36. Targeting tumor-associated immune suppression with selective protein kinase A type I (PKAI) inhibitors may enhance cancer immunotherapy.
Hussain M; Shah Z; Abbas N; Javeed A; Mukhtar MM; Zhang J
Med Hypotheses; 2016 Jan; 86():56-9. PubMed ID: 26804598
[TBL] [Abstract][Full Text] [Related]
37. MAPRE1 promotes cell cycle progression of hepatocellular carcinoma cells by interacting with CDK2.
Liang XH; Feng ZP; Liu FQ; Yan R; Yin LY; Shen H; Lu HL
Cell Biol Int; 2020 Nov; 44(11):2326-2333. PubMed ID: 32770827
[TBL] [Abstract][Full Text] [Related]
38. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
39. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
[TBL] [Abstract][Full Text] [Related]
40. Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.
Eguchi T; Itadani H; Shimomura T; Kawanishi N; Hirai H; Kotani H
Mol Cancer Ther; 2009 Jun; 8(6):1460-72. PubMed ID: 19509251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
